OTTAWA, June 27, 2012 /CNW/ - Annidis Corporation (TSX-V:RHA), creator of the Annidis RHA™ imaging technology that assists eye-care professionals screen, detect, diagnose and manage ocular diseases including age related macular degeneration and diabetic retinopathy, today announced that it has obtained TSX Venture Exchange approval to amend certain stock options granted to directors, officers, employees and consultants of Corporation between July 8, 2008 and September 22, 2009. A total of 3,525,000 stock options that were to expire between July 8, 2012 and September 22, 2012 at exercises prices between $0.32 and $0.36 will be extended by four additional years with the exercise price increased to $0.40 per share.
The Corporation also announces that it has granted an aggregate of 50,000 options to employees and consultants of the Corporation. Each option entitles the holder to acquire one Annidis common share at an exercise price of $0.40. These options will expire on June 27, 2016.
About Annidis Corporation
Annidis (TSX-V:RHA) is dedicated to researching and developing instrumentation to assist in the early detection and monitoring of diseases of the eye. The Company's RHATM is an ocular pathology management system that integrates advanced multi-spectral imaging and analytic software for early detection and management of ocular pathologies such as age-related macular degeneration and diabetic retinopathy. The RHA system is the result of a multiyear research and development effort by the Annidis team in collaboration with leading eye care professionals and researchers in US and Canada including the Ottawa Eye Institute, Toronto Western Hospital and numerous eye care clinics in US and Canada.
This news release may contain "forward-looking information" within the meaning of applicable Canadian securities legislation. Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope", and "continue" (or the negative thereof), and words and expressions of similar import are intended to identify forward-looking statements. Certain material factors or assumptions are implied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other such filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent ligation; regulatory approval of products in development; changes in government regulation or regulatory approval processes; government and third party reimbursement; dependence on strategic partnerships; intensifying competition; rapid technological change in the industry; anticipated future losses; the ability to access capital; and the ability to attract and retain key personnel. All forward-looking information presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Corporation does not undertake to update any forward-looking statements; such statements speak only as of the date made.
For further information:
Gerald Slemko, CEO
Email: [email protected]
(416) 815-0700 ext. 264
Email: [email protected]